NCT07532174Recruiting
Efferon LPS Hemoadsorption in Cardiac Surgery Patients
Intraoperative and Early Postoperative Use of Lipopolysaccharide Adsorption (Efferon LPS) in Cardiac Surgery Patients to Reduce the Incidence of Multiple Organ Dysfunction Syndrome in the Postoperative Period
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Brief summary (registry, in English)
This randomized controlled study aims to evaluate the efficacy and safety of intraoperative and early postoperative hemoadsorption using the Efferon® LPS device in patients undergoing cardiac surgery with cardiopulmonary bypass in reducing the incidence and severity of multiple organ dysfunction syndrome (MODS) in the postoperative period. Each patient in the treatment group will undergo two hemoadsorption sessions: first during cardiopulmonary bypass (CPB) at the time of cardiac surgery, with the duration determined by the CPB time, and second within 24 hours postoperatively, for a minimum duration of 6 hours.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 9 Apr 2026
- Start date
- 22 Apr 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Efferon JSC
- NCT number
- NCT07532174
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 22 Apr 2026 to the primary completion date, 31 Dec 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Ongoing immunosuppressive therapy, including corticosteroids or cytotoxic agents, excluding standard perioperative medications
Other illness
- Severe chronic liver disease, defined as Child-Pugh class C (\>10 points) or clinically manifest hepatic failure
- Dialysis-dependent chronic kidney disease (CKD)
- Any other clinical condition that, in the investigator's opinion, would preclude the patient's participation in the study
Other
- Procalcitonin ≥2 ng/mL
Who the study is looking for
- Adult patients undergoing elective or emergency cardiac surgery with the use of cardiopulmonary bypass (CPB).
- EuroSCORE II ≥6%
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Regional State Budgetary Healthcare Institution "Altai Regional Cardiological Dispensary" Coordinator of this site? Confirm its status | Barnaul | Russia | Recruiting |
| Almazov National Medical Research Centre Coordinator of this site? Confirm its status | Saint Petersburg | Russia | Recruiting |
| Pavlov First Saint Petersburg State Medical University Coordinator of this site? Confirm its status | Saint Petersburg | Russia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.